These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3715874)

  • 1. Effect of 3,4-diaminopyridine on the survival of mice injected with botulinum neurotoxin type A, B, E, or F.
    Siegel LS; Johnson-Winegar AD; Sellin LC
    Toxicol Appl Pharmacol; 1986 Jun; 84(2):255-63. PubMed ID: 3715874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ineffectiveness of 3,4-diaminopyridine as a therapy for type C botulism.
    Siegel LS; Price JI
    Toxicon; 1987; 25(9):1015-8. PubMed ID: 3433299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism.
    Simpson LL
    Infect Immun; 1986 Jun; 52(3):858-62. PubMed ID: 3011675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the action of types A and F botulinum toxin at the rat neuromuscular junction.
    Kauffman JA; Way JF; Siegel LS; Sellin LC
    Toxicol Appl Pharmacol; 1985 Jun; 79(2):211-7. PubMed ID: 2988154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidotal treatment of botulism in rats by continuous infusion with 3,4-diaminopyridine.
    Machamer JB; Vazquez-Cintron EJ; O'Brien SW; Kelly KE; Altvater AC; Pagarigan KT; Dubee PB; Ondeck CA; McNutt PM
    Mol Med; 2022 Jun; 28(1):61. PubMed ID: 35659174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin.
    Adler M; Macdonald DA; Sellin LC; Parker GW
    Toxicon; 1996 Feb; 34(2):237-49. PubMed ID: 8711757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 3,4-diaminopyridine reverses paralysis in botulinum neurotoxin-intoxicated diaphragms through two functionally distinct mechanisms.
    Bradford AB; Machamer JB; Russo TM; McNutt PM
    Toxicol Appl Pharmacol; 2018 Feb; 341():77-86. PubMed ID: 29366638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Symptomatic treatment of botulism with a clinically approved small molecule.
    Vazquez-Cintron E; Machamer J; Ondeck C; Pagarigan K; Winner B; Bodner P; Kelly K; Pennington MR; McNutt P
    JCI Insight; 2020 Jan; 5(2):. PubMed ID: 31996484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of 4-aminopyridine on the development of experimental botulism].
    Morrison VV; Kryzhanovskiĭ GN
    Biull Eksp Biol Med; 1985 Oct; 100(10):445-7. PubMed ID: 2996654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recovery from botulinum neurotoxin poisoning in vivo.
    Keller JE
    Neuroscience; 2006 May; 139(2):629-37. PubMed ID: 16490322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-Vivo Neutralization of Botulinum Neurotoxin Serotype E Using Rabbit Polyclonal Antibody Developed against BoNT/E Light Chain.
    Rani S; Ponmariappan S; Sharma A; Kamboj DV; Jain AK
    Protein Pept Lett; 2017; 24(6):495-502. PubMed ID: 28260503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle.
    Adler M; Keller JE; Sheridan RE; Deshpande SS
    Toxicon; 2001; 39(2-3):233-43. PubMed ID: 10978741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of severe botulism with 3,4-diaminopyridine]].
    Dock M; Ben Ali A; Karras A; Misset B; Garrouste-Orgeas M; Deletie E; Goldstein F; Carlet J
    Presse Med; 2002 Apr; 31(13):601-2. PubMed ID: 11984982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Complex pathogenetic therapy of experimental botulism].
    Kryzhanovskiĭ GN; Morrison VV
    Biull Eksp Biol Med; 1987 Nov; 104(11):543-5. PubMed ID: 2823931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Formulating a new basis for the treatment against botulinum neurotoxin intoxication: 3,4-Diaminopyridine prodrug design and characterization.
    Zakhari JS; Kinoyama I; Hixon MS; Di Mola A; Globisch D; Janda KD
    Bioorg Med Chem; 2011 Nov; 19(21):6203-9. PubMed ID: 21975066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of pharmacologic antagonists to deduce commonalities of biologic activity among clostridial neurotoxins.
    Simpson LL
    J Pharmacol Exp Ther; 1988 Jun; 245(3):867-72. PubMed ID: 2455038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of 3,4-diaminopyridine on acetylcholine release at the frog neuromuscular junction.
    Durant NN; Marshall IG
    Eur J Pharmacol; 1980 Oct; 67(2-3):201-8. PubMed ID: 6970132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and treatment of botulism in lions.
    Greenwood AG
    Vet Rec; 1985 Jul; 117(3):58-60. PubMed ID: 4049682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps.
    Adler M; Capacio B; Deshpande SS
    Toxicon; 2000 Oct; 38(10):1381-8. PubMed ID: 10758273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in neuromuscular transmission in myasthenia gravis by 3,4-diaminopyridine.
    Lundh H; Nilsson O; Rosén I
    Eur Arch Psychiatry Neurol Sci; 1985; 234(6):374-7. PubMed ID: 2992990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.